Adam K. Simpson - Dec 21, 2022 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Stock symbol
ICVX
Transactions as of
Dec 21, 2022
Transactions value $
-$586,336
Form type
4
Date filed
12/23/2022, 06:00 PM
Previous filing
Nov 14, 2022
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Sale -$598K -66.8K -22.87% $8.96 225K Dec 21, 2022 Direct F1, F2
transaction ICVX Common Stock Options Exercise $12.1K +14.4K +6.38% $0.84* 239K Dec 23, 2022 Direct
holding ICVX Common Stock 532K Dec 21, 2022 By family trust
holding ICVX Common Stock 129K Dec 21, 2022 By family trust
holding ICVX Common Stock 129K Dec 21, 2022 By family trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Stock Option (Right to Buy) Options Exercise $0 -14.4K -30% $0.00 33.5K Dec 23, 2022 Common Stock 14.4K $0.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the sale by the Reporting Person, pursuant to a Rule 10b5-1 trading plan, of a portion of the shares of the Issuer purchased by the Reporting Person via exercise of incentive stock options during 2022. These shares are being sold by the Reporting Person prior to the end of 2022 in order to trigger a disqualifying disposition of such shares and to eliminate the alternative minimum tax that would otherwise arise as a result of the Reporting Person's exercise of such incentive stock options during 2022, with the remainder of the purchased shares continued to be held by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.54 to $9.41. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares subject to the option vested on 2/21/2021, and 1/48th of the shares subject to the option vest monthly thereafter.